Comparison of two regimens for the treatment of meningoencephalomyelitis of unknown etiology

Journal of Veterinary Internal Medicine

Volumn 23, Issue 3, 2009, Pages 520-526

  Smith, P M ^a,b   Stalin, C E ^a   Shaw, D ^a   Granger, N ^a   Jeffery, N D ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

CSF analysis; Encephalitis; Inflammatory; Meningitis; Noninfectious

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ANIMAL; ANIMAL DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOG DISEASE; DRUG COMBINATION; MENINGOENCEPHALITIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE;

ANIMALS; ANTINEOPLASTIC AGENTS; DOG DISEASES; DOGS; DRUG THERAPY, COMBINATION; IMMUNOSUPPRESSIVE AGENTS; MENINGOENCEPHALITIS; TREATMENT FAILURE;

ANIMALIA; CANIS FAMILIARIS;

EID: 67449093608     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2009.0299.x     Document Type: Article

References (30)

1. Jung D-I, Kang B-T, Park C, et al. A comparison of combination therapy (cyclosporine plus prednisolone) with sole prednisolone therapy in 7 dogs with necrotizing meningoencephalitis. J Vet Med Sci 2007;69:1303-1306.
2. Muñana KR, Luttgen PJ. Prognostic factors for dogs with granulomatous meningoencephalomyelitis: 42 cases (1982-1996). J Am Vet Med Assoc 1998;212:1902-1906.
3. Nuhsbaum MT, Powell CC, Gionfriddo JR, Cuddon PA. Treatment of granulomatous meningoencephalomyelitis in a dog. Vet Ophthalmol 2002;5:29-33.
4. Adamo FP, O'Brien RT. Use of cyclosporine to treat granulomatous meningoencephalitis in three dogs. J Am Vet Med Assoc 2004;225:1211-1216, 1196.
5. Gnirs K. Ciclosporin treatment of suspected granulomatous meningoencephalomyelitis in three dogs. J Small Anim Pract 2006; 47:201-206.
6. Zarfoss M, Schatzberg S, Venator K, et al. Combined cytosine arabinoside and prednisone therapy for meningoencephalitis of unknown aetiology in 10 dogs. J Small Anim Pract 2006;47:588-595.
7. Coates JR, Barone G, Dewey CW, et al. Procarbazine as adjunctive therapy for treatment of dogs with presumptive antemortem diagnosis of granulomatous meningoencephalomyelitis: 21 cases (1998-2004). J Vet Intern Med 2007;21:100-106.
8. Menaut P, Landart J, Behr S, et al. Treatment of 11 dogs with meningoencephalomyelitis of unknown origin with a combination of prednisolone and cytosine arabinoside. Vet Rec 2008;162: 241-245.
9. Houthoff HJ, Poppema S, Ebels EJ, Elema JD. Intracranial malignant lymphomas. Acta Neuropathol (Berlin) 1978;44: 203-210.
10. Vandevelde M, Fatzer R, Fankhauser R. Immunohistological studies on primary reticulosis of the canine brain. Vet Pathol 1981;18:577-588.
11. Perini P, Calabrese M, Rinaldi L, Gallo P. Cyclophosphamide-based combination therapies for autoimmunity. Neurol Sci 2008;29:S233-S234.
12. http://clinicaltrials.gov/ct2/info/glossary
13. Cordy DR. Canine granulomatous meningoencephalomyelitis. Vet Pathol 1979;16:325-333.
14. Summers BA, Cummings JF, De Lahunta A. Veterinary Neuropathology, 1st ed. St Louis, MO: Mosby-Year Book, Inc; 1994:203-204.
15. Kipar A, Baumgartner W, Vogl C, et al. Immunohistochemical characterization of inflammatory cells in brains of dogs with granulomatous meningoencephalitis. Vet Pathol 1998;35:43-52.
16. Camiener GW. Studies of the enzymatic deamination of cytosine arabinoside-II: Properties of the deaminase of human liver. Biochem Pharmacol 1967;16:1681-1689.
17. Scott-Moncrieff JC, Chan TC, Samuels ML, et al. Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs. Cancer Chemother Pharmacol 1991;29:13-18.
18. Slevin ML, Piall EM, Aherne GW, et al. The pharmacokinetics of subcutaneous cytosine arabinoside in patients with acute myelogenous leukaemia. Br J Clin Pharmacol 1981;12:507-510.
19. Cozzarelli NR. The mechanism of action of inhibitors of DNA synthesis. Ann Rev Biochem 1977;46:641-668.
20. Balis FM, Poplack DG. Central nervous system pharmacology of antileukemic drugs. Am J Pediatr Hematol Oncol 1989; 11:74-86.
21. Groothuis DR, Benalcazar H, Allen CV, et al. Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of administration. Brain Res 2000;856:281-290.
22. Fukuda S. Incidence of pyometra in colony-raised Beagle dogs. Exp Anim 2001;50:325-329.
23. Faldyna M, Laznicka A, Toman M. Immunosuppression in bitches with pyometra. J Small Anim Pract 2001;42:5-10.
24. Cox PJ. Cyclophosphamide cystitis: Identification of acrolein as the causative agent. Biochem Pharmacol 1979;28:2045-2049.
25. Charney SC, Bergman PJ, Hohenhaus AE, McKnight JA. Risk factors for sterile hemorrhagic cystitis in dogs with lymphoma receiving cyclophosphamide with or without concurrent administration of furosemide: 216 cases (1990-1996). J Am Vet Med Assoc 2003;222:1388-1393.
26. Martin F, Lauwerys B, Lefebvre C, et al. Side-effects of intravenous cyclophosphamide pulse therapy. Lupus 1997;6:254-257.
27. Ruslander D, Moore AS, Gliatto JM, et al. Cytosine arabinoside as a single agent for the induction of remission in canine lymphoma. J Vet Intern Med 1994;8:299-301.
28. Penn I. Cancers following cyclosporine therapy. Transplantation 1987;43:32-35.
29. Snanoudj R, Kriaa F, Arzouk N, et al. Single-center experience with cyclosporine therapy for kidney transplantation: Analysis of a twenty-year period in 1200 patients. Transplant Proc 2004; 36:83S-88S.
30. Dantal J, Pohanka E. Malignancies in renal transplantation: An unmet medical need. Nephrol Dial Transplant 2007;22(Suppl 1):i4-i10.